New Advances in General Biomedical Applications of PAMAM Dendrimers

Autor(es)

de Araujo, Renan Vinicius ^[1] ; Santos, Soraya da Silva ^[1] ; Ferreira, Elizabeth Igne ^[1] ; Giarolla, Jeanine ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Fac Pharmaceut Sci, Dept Pharm, Lab Design & Synth Chemotherapeut Potentially Act, 580 Bldg 13, BR-05508900 Sao Paulo - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: Molecules; v. 23, n. 11 NOV 2018.
• Citações Web of Science: 14

Resumo

Dendrimers are nanoscopic compounds, which are monodispersed, and they are generally considered as homogeneous. PAMAM (polyamidoamine) was introduced in 1985, by Donald A. Tomalia, as a new class of polymers, named starburst polymers'. This important contribution of Professor Tomalia opened a new research field involving nanotechnological approaches. From then on, many groups have been using PAMAM for diverse applications in many areas, including biomedical applications. The possibility of either linking drugs and bioactive compounds, or entrapping them into the dendrimer frame can improve many relevant biological properties, such as bioavailability, solubility, and selectivity. Directing groups to reach selective delivery in a specific organ is one of the advanced applications of PAMAM. In this review, structural and safety aspects of PAMAM and its derivatives are discussed, and some relevant applications are briefly presented. Emphasis has been given to gene delivery and targeting drugs, as advanced delivery systems using PAMAM and an incentive for its use on neglected diseases are briefly mentioned. (AU)

• Processo FAPESP: 17/21154-7 - Dendrímero de poliamidoamina (PAMAM) de primeira geração: planejamento e síntese de pró-fármaco potencialmente ativo em tuberculose
• Beneficiário: Renan Vinicius de Araujo
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 15/19438-1 - Síntese e estudos de liberação de compostos bioativos a partir de pró-fármacos e fármacos dirigidos dendriméricos potencialmente ativos em doenças negligenciadas
• Beneficiário: Jeanine Giarolla Vargas
• Modalidade de apoio: Auxílio à Pesquisa - Regular